Last week changed the board again. AZN / DATROWAY® printed approved early on May 22, ahead of its June 2 action date. That removes one large-cap clock from the forward board.
IRWD / LINZESS® did not have a public decision announcement in the source check. The posted May 24 PDUFA fell on a Sunday, followed by the Memorial Day holiday on Monday May 25, so the practical action window remains open into Tuesday May 26 or later.
The next live stack is now: IRWD, MNKD, CING, SPRO, ACHV, ARQT, LNTH, and IONS. Denser than last week, but cleaner in shape: one approval already printed, one weekend/holiday clock still unresolved, and several late-June decisions now close enough to matter.
|
✓
|
AZN / DATROWAY® — APPROVED · May 22
Approved for first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy. That June 2 clock is now resolved and comes off the forward board.
|
|
··
|
IRWD / LINZESS® — STILL IN WINDOW · PDUFA May 24
No public approval or CRL announcement was found in the source check. Because the PDUFA date fell on a Sunday followed by Memorial Day, this remains an open action-window item rather than a cleanly resolved catalyst.
|
|
!
|
ACHV / cytisinicline — REFRAMED · CRL expected by Jun 20
Still an FDA event, but not a live approval watch in the usual sense. Achieve has said it expects to receive a CRL on or before the June 20 PDUFA date due to inspection issues at a prior third-party manufacturer, with resubmission planned after naming Adare Pharma Solutions as commercial manufacturer.
|
| PDUFA | Window | Ticker | Event | PoA / Status |
| Sun May 24 | Tue May 26+ | IRWD | LINZESS® / FC, ages 2–5 | 65% |
| Fri May 29 | Fri May 29 | MNKD | Afrezza / peds T1D & T2D, ages 4–17 | 72% |
| Sun May 31 | Fri 29 / Mon Jun 1 | CING | CTx-1301 / ADHD | 75% |
| Thu Jun 18 | Thu Jun 18 | SPRO | tebipenem HBr / cUTI, incl. pyelo | 92.5% |
| Sat Jun 20 | Thu 18 / Mon 22 | ACHV | cytisinicline / smoking cessation | CRL exp. |
| Mon Jun 29 | Mon Jun 29 | ARQT | ZORYVE® cream / psoriasis, ages 2–5 | 95%+ |
| Mon Jun 29 | Mon Jun 29 | LNTH | LNTH-2501 / SSTR+ NET imaging | 92.5% |
| Tue Jun 30 | Tue Jun 30 | IONS | TRYNGOLZA® / severe HTG | 92.5% |
| IRWD $IRWD · LINZESS® · FC ages 2–5 | PDUFA: Sun May 24 PoA 65% |
This remains the immediate unresolved clock. The setup is a pediatric label expansion for an established GI franchise, but the age group matters. LINZESS is already approved in older pediatric populations, while this review pushes into children ages 2–5, where safety sensitivity is higher and the boxed warning against use under age 2 keeps the risk conversation alive.
| MNKD $MNKD · Afrezza · peds T1D & T2D | PDUFA: Fri May 29 PoA 72% |
A pediatric label expansion for an already approved inhaled insulin product. The commercial hook is obvious: needle-free mealtime insulin for children and adolescents ages 4–17 with type 1 or type 2 diabetes. The regulatory risk is specific: INHALE-1 missed HbA1c noninferiority on the full ITT analysis, while MannKind’s defense leans on a modified analysis excluding one nonadherent patient. The FDA decision likely turns on whether reviewers accept that sensitivity case alongside stable pulmonary function, patient satisfaction, and weight effects.
| CING $CING · CTx-1301 · ADHD | PDUFA: Sun May 31 PoA 75% |
A 505(b)(2) ADHD setup with a live FDA date at month-end. The story is straightforward: known active ingredient, differentiated timed-release platform, and an attempt to carve out a full-day symptom-control position in a crowded stimulant market. The key FDA nuance remains manufacturing and CMC, where the company has said it is responding to agency information requests.
| SPRO $SPRO · tebipenem HBr · cUTI, incl. pyelo | PDUFA: Thu Jun 18 PoA 92.5% |
One of the cleaner smaller-cap setups on the board. The asset is partnered with GSK, the PIVOT-PO package supports the resubmission, and the core pitch remains simple: a potential first oral carbapenem option for complicated urinary tract infections, including pyelonephritis.
| ACHV $ACHV · cytisinicline · smoking cessation | PDUFA: Sat Jun 20 CRL exp. |
The clinical story remains strong, but the regulatory setup has changed. Achieve has said it expects a CRL by the June 20 PDUFA date tied to manufacturing/inspection issues at a prior third-party manufacturer. This is now a timing/reset story, not a clean approval watch.
| ARQT $ARQT · ZORYVE® 0.3% · psoriasis, ages 2–5 | PDUFA: Mon Jun 29 PoA 95%+ |
A pediatric label expansion around an already approved and commercialized dermatology franchise. The capped PoA reflects a heavily de-risked label-expansion setup, not a guarantee.
| LNTH $LNTH · Ga 68 edotreotide · SSTR+ NET imaging | PDUFA: Mon Jun 29 PoA 92.5% |
Now inside the forward window. The FDA previously extended the review by three months to June 29 to review manufacturing-related information. Importantly, the company said the extension was not related to efficacy or safety data.
| IONS $IONS · olezarsen · severe HTG | PDUFA: Tue Jun 30 PoA 92.5% |
A high-confidence late-June label-expansion setup. Olezarsen is already approved in familial chylomicronemia syndrome, and the current Priority Review is for severe hypertriglyceridemia. This is not the next hard clock, but it now belongs on the board.
The board rotates by both result and correction.
AZN is off by early approval. IRWD remains unresolved after a weekend/holiday PDUFA. ACHV is no longer a clean approval watch. LNTH and IONS move into the forward window. The next real work shifts to:
| IRWD | → | MNKD | → | CING | → | SPRO |
| ACHV | → | ARQT / LNTH | → | IONS |
That is the queue.
Informational only · Not investment advice · Biotech carries risk of total loss